Can you take Bitolterol with Sorbitol?

Sorbitol has a moderate potential interaction with Dehydration.

Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia. Excessive loss of water and electrolytes may may also cause hypernatremia. Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia. Patients with sodium imbalances or dehydration should be closely monitored.

Bitolterol has a moderate potential interaction with Diabetes Mellitus.

Adrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.

Sorbitol has a moderate potential interaction with Diabetes Mellitus.

Sorbitol is converted to glucose in the body. The use of sorbitol is not recommended as an alternative sweetener in patients with diabetes. Sorbitol is one of the end products of glucose metabolism that results in some of the late complications of diabetes.

Sorbitol has a major potential interaction with Gastrointestinal Obstruction.

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

Bitolterol has a moderate potential interaction with Heart Disease.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Sorbitol has a major potential interaction with Heart Failure.

The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria. In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction. Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics. Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).

Bitolterol has a moderate potential interaction with High Blood Pressure.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Sorbitol has a moderate potential interaction with Hypernatremia.

Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia. Excessive loss of water and electrolytes may may also cause hypernatremia. Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia. Patients with sodium imbalances or dehydration should be closely monitored.

Bitolterol has a moderate potential interaction with Hyperthyroidism.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Bitolterol has a moderate potential interaction with Hypokalemia.

Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.

Sorbitol has a moderate potential interaction with Hyponatremia.

Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia. Excessive loss of water and electrolytes may may also cause hypernatremia. Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia. Patients with sodium imbalances or dehydration should be closely monitored.

Sorbitol has a major potential interaction with Inflammatory Bowel Disease.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

Sorbitol has a major potential interaction with Renal Dysfunction.

The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria. In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction. Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics. Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).

Bitolterol has a moderate potential interaction with Seizures.

Adrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.